(JAGX) to Attend the 2015 KC Animal Health Investment Forum

Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that Lisa Conte, Jaguar’s President and CEO, and John Kallassy, Chief Financial and Operating Officer, will be attending the 2015 KC Animal Health Investment Forum at the Kansas City Convention Center on Tuesday, September 1.

The KC Animal Health Investment Forum showcases animal health and nutrition companies from around the world. It provides a unique opportunity for emerging companies to introduce new technologies to investment firms, venture capital funds and other animal health companies. The Forum offers one of the only opportunities for companies in the animal health sector to present their vision and business plan to potential investors. Past presenting companies have gained increased exposure within the investment community and animal health industry, in many cases directly resulting in new licensing agreements and distribution contracts.

Jaguar management will be available for one-on-one meetings during the conference. To schedule a meeting, please contact KCSA Strategic Communications at jaguar@kcsa.com.

About Jaguar Animal Health, Inc.

Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals. Canalevia^™ is Jaguar’s lead prescription drug product candidate for the treatment of various forms of watery diarrhea in dogs. Neonorm^™ Calf is the Company’s lead non-prescription product. Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree, which is sustainably harvested. Neonorm is a standardized botanical extract derived from the Croton lechleri tree. Canalevia and Neonorm are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar has filed nine Investigational New Animal Drug applications, or INADs, with the FDA and intends to develop species-specific formulations of Neonorm in six additional target species, and formulations of Canalevia for cats, horses and dogs.

For more information, please visit www.jaguaranimalhealth.com.

 

KCSA Strategic Communications
Garth Russell, 212-896-1250
grussell@kcsa.com
Tram Bui, 212-896-1290
tbui@kcsa.com
Jaguar-JAGX